How can a vicinal amino alcohol scaffold modulate P2–P4 interactions in macrocyclic NS3/4A protease ligands?The (3R,4R)-rel-N-Boc-3-amino-4-hydroxypyrrolidine framework exhibits a stereoelectronic profile that positions the C-3 amine and C-4 hydroxyl in a trans diequatorial orientation. This spatial arrangement is exploited in the assembly of macrocyclic acylsulfonamide-based hepatitis C virus protease inhibitors, where the pyrrolidine core replaces a canonical proline residue to alter amide bond geometry and desolvation penalties at the S2 subsite. In a typical industrial batch record developed for a late-stage intermediate compliant with ICH Q7 section 8.4, the free primary amine is coupled to a quinoline- or isoquinoline-derived carboxylic acid using HATU (1.20 eq) in anhydrous THF/N-methyl-2-pyrrolidone (4:1 v/v) at –5 ± 2 °C, with N,N-diisopropylethylamine (3.00 eq) added over 45 min through a peristaltic pump to maintain pH 8.0–8.3. The hydroxy group remains unprotected during this step; however, when the downstream sequence involves a Mitsunobu inversion or an oxidation to the ketone, temporary silylation with TBSCl (1.05 eq, imidazole 2.20 eq) in DMF at 23 ± 2 °C under nitrogen is inserted to prevent competing O-acylation. Residual palladium from an earlier Sonogashira step on the quinoline fragment must be below 50 ppm (measured by ICP-MS per USP <233>) before the coupling to avoid catalyst poisoning and desulfurization side-products. The terminal pharmaceutical substance refined from this intermediate typically falls under the category of direct-acting antivirals targeting NS3/4A, and the process stream is monitored for genotoxic impurities by LC-MS/MS with a reporting threshold of 1.0 µg/g. Extended hold times of the activated ester beyond 30 min at 0 °C lead to epimerization up to 4% at the adjacent stereocenter, necessitating a controlled addition sequence. The Boc-carbamate on the pyrrolidine nitrogen is retained through the macrocyclization and cleaved only after ring closure using trifluoroacetic acid (50% v/v in DCM) containing triisopropylsilane (2.5% v/v) and water (2.5% v/v) at 20–25 °C over 2 h.The reactivity of the C-4 hydroxyl as a nucleophile in the presence of the C-3 primary amine creates a chemoselectivity challenge that is managed by pH-controlled acylation. When the synthetic route demands selective sulphonylation of the amine, the hydroxyl is transiently protected in situ as its trimethylsilyl ether by treating the starting material with hexamethyldisilazane (2.0 eq) and saccharin (0.01 eq) in refluxing THF. Methanesulfonyl chloride (1.05 eq) added to the resulting solution at –10 °C produces the N-sulfonamide with 98+% regioselectivity; the silyl group is removed without isolation by quenching into aqueous citric acid (10% w/w). The crude product is crystallised from ethyl acetate/n-heptane (1:3) to yield an intermediate with differential scanning calorimetry onset melting at 122.3 ± 0.5 °C. Batch-to-batch consistency for the water content—dried under vacuum (≤10 mbar) at 45 °C for 16 h—must meet the criterion of <0.15% w/w by Karl Fischer titration (USP <921> Method Ic) before use in subsequent organometallic steps. Failure to achieve this dryness threshold causes erratic conversion in Grignard additions where the Boc group remains labile, generating a des-Boc impurity that co-elutes with the product in reversed-phase HPLC (C18 column, acetonitrile/0.1% TFA gradient, detection at 210 nm). The final drug substance produced from this intermediate exhibits a specified purity of 99.8% area and a single unknown impurity limit of ≤0.10%, verified against a reference standard qualified by quantitative NMR. What governs the reversibility of oxazaborolidine formation when the starting vicinal amino alcohol adopts a trans-diequatorial arrangement?Coordination of the (3R,4R)-3-amino-4-hydroxy-N-Boc-pyrrolidine with borane reagents generates a chiral oxazaborolidine catalyst system whose enantioselectivity in prochiral ketone reduction depends critically on the B–N bond length and the dihedral angle of the fused [3.3.0] bicyclics. In a standard catalyst preparation sequence executed at pilot scale (200 L glass-lined reactor), the compound is dissolved in anhydrous THF (0.15 M) and treated with borane–dimethyl sulfide complex (1.05 eq of BH₃, measured via hydride content titration) at 0 °C under argon. The mixture is heated to 66 °C for 90 min to expel dimethyl sulfide while forming the heterocycle, and the resulting solution is immediately used for the asymmetric reduction of substituted acetophenones. For the model substrate 2’-chloroacetophenone, a substrate-to-catalyst ratio of 10:1 mol/mol at –20 °C with 1.0 M borane–THF complex as the stoichiometric reductant yields (R)-1-(2-chlorophenyl)ethanol in 96% ee (chiral GC, CP-Chirasil-Dex CB column, isothermal 120 °C) and 92% isolated yield after acid–base extraction. The Boc-protecting group remains intact under these conditions; however, the catalyst becomes irreversibly deactivated if the reaction temperature exceeds +10 °C due to B–O oligomerization that precipitates as a white solid. This precipitate has been characterized by 11B NMR (δ 18.2 ppm, BF₃·OEt₂ reference) and correlates with a loss of enantioselectivity to <20% ee. The process vessel must be rendered oxygen-free via three nitrogen pressurization-vent cycles to 0.5 bar(g) before initiating the catalyst formation, as dissolved oxygen quenches the borane intermediate and generates a dark-colored impurity that fouls the reactor temperature probes.The free amino group of the scaffold, if prematurely deprotected, forms competing borane–amine adducts that shift the catalyst equilibrium towards an inactive species. Consequently, the N-Boc derivative is used directly without any acidic work-up in the catalyst-forming step. After the reduction, the chiral alcohol product is separated and the catalyst residue quenched with methanol (5 volumes) at 0–5 °C, causing hydrogen evolution and precipitation of boric acid. The aqueous phase is distilled under reduced pressure to recover THF for reuse; the residual boric acid cake is characterized by ash content exceeding 99.5% and can be sent to waste treatment. The recovered (R)-alcohol is assayed by HPLC with a UV detection at 254 nm and its optical rotation measured at 589 nm according to Ph. Eur. monograph 2.2.7. Typical specifications demand a chiral purity of ≥99.0% area and absence of the (S)-antipode above the limit of quantification (0.05%). The major identifiable risk in this process is the co-distillation of dimethyl sulfide with the product, which imparts an odor and requires additional carbon treatment. The final chiral intermediate is employed in the preparation of a selective estrogen receptor degrader (SERD) clinical candidate, where the (R)-benzylic alcohol serves as the precursor to an ether-linked side chain. The secondary hydroxyl at C-4 can be oxidized to a ketone without disturbing the Boc-carbamate or the C-3 amine when the latter is masked as its 2,4-dimethoxybenzyl (DMB) imine. This transient protection is performed by treating the free amino alcohol with 2,4-dimethoxy benzaldehyde (1.05 eq) in dichloromethane containing magnesium sulfate at reflux (40 °C), yielding the imine as a yellow oil after filtration and evaporation. The resultant crystalline imine is dissolved in acetone and oxidized with freshly prepared Jones reagent (2.67 M CrO₃ in dilute H₂SO₄, 1.20 eq relative to the alcohol) at 0–5 °C, added dropwise over 2 h. Quenching into ice-cold 2-propanol followed by extraction with ethyl acetate and vacuum distillation gives the 3-DMB-imino-4-oxopyrrolidine intermediate as a pale brown solid. The ketone then undergoes reductive amination with cyclopropylamine (1.50 eq) and sodium cyanoborohydride (1.80 eq) in methanol/acetic acid (10:1 v/v) at 20 °C to install a cyclopropylamino group with 84% diastereomeric excess in favor of the cis addition product. Following DMB cleavage with ceric ammonium nitrate (2.50 eq) in acetonitrile/water (5:1), the free diamine is exposed to bis(2,5-dioxopyrrolidin-1-yl) carbonate in dichloromethane to form a cyclic urea. This sequence leads to a constrained bicyclic diamine core that serves as the P1 fragment in a series of orally bioavailable β-site APP-cleaving enzyme 1 (BACE1) inhibitors. The final active pharmaceutical ingredient manufactured with this fragment is required to meet a residual cerium specification of ≤40 ppm, performed via inductively coupled plasma mass spectrometry on the dried drug substance. Should the oxidation exceed +5 °C, over-oxidation to the carboxylic acid occurs to an extent of 7–12%, as confirmed by 13C NMR (δ 172.9 ppm), and the batch must be rejected.Should residual moisture exceed 0.2% w/w during Boc-cleavage in the presence of an acid-labile glycosidic linkage?The use of anhydrous hydrogen chloride in 1,4-dioxane (4.0 M, 5.0 eq) at 10 ± 2 °C to remove the N-Boc group from the pyrrolidine nitrogen liberates the corresponding ammonium chloride salt while preserving the C-4 hydroxyl and C-3 amine in their native protonated state. This deprotection protocol is critical when the compound is employed as a chiral scaffold for the synthesis of indolizidine alkaloid mimetics that possess inherent glycosidase inhibition activity. After deprotection, the resultant ammonium salt is neutralized with a polymer-supported carbonate base (e.g., Ambersep 900 OH form, 3.0 eq by exchange capacity) in methanol to yield the free amino alcohol, which is immediately engaged in a Pictet–Spengler cyclization with 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl aldehyde (1.00 eq) in acetonitrile containing catalytic trifluoroacetic acid (0.05 eq). The cyclization mixture is stirred at 60 °C for 18 h under argon, and the resulting iminosugar precursor precipitates upon cooling to –20 °C. The isolated solid exhibits a specific rotation [α]D20 = –38.4° (c 1.0, CHCl₃) and is advanced to global deprotection via catalytic hydrogenolysis (H₂ 50 psi, 10% Pd/C, THF/ethanol/water) to generate a polyhydroxylated indolizidine with Ki = 12 nM against α-glucosidase from Saccharomyces cerevisiae (assay conducted at pH 6.8, 37 °C). The pivotal requirement throughout this sequence is that the hygroscopic ammonium salt must be handled in a glovebag under a nitrogen atmosphere with a relative humidity below 30% at 22 °C; exposure to ambient conditions for >15 min raises the water content above 0.5%, which subsequently hydrolyses the benzylidene acetal protection on the sugar during the acid-catalyzed cyclization, leading to complex mixtures that are not reworkable.For the manufacturing of an investigative new drug batch under FDA 21 CFR 312.23, the amino alcohol intermediate after Boc removal is submitted to an enzymatic resolution to upgrade the enantiomeric purity. Candida antarctica lipase B immobilized on acrylic resin (Novozym 435) is added at 10% w/w relative to the racemic amine, and the acetylation is carried out with vinyl acetate (3.0 eq) in methyl tert-butyl ether at 45 °C for 48 h. The enzyme selectively acetylates the (3R,4R)-amine, leaving the undesired enantiomer untouched. After filtration of the biocatalyst and chromatography on silica gel (eluent: dichloromethane/methanol/triethylamine 95:4.5:0.5), the O-acetyl-N-deblocked intermediate is isolated in >99.5% ee (chiral HPLC, Chiralpak IA column, hexane/ethanol/diethylamine 80:20:0.1). The recovered biocatalyst can be reused for 8 consecutive cycles with only 5% loss in activity before replacement due to mechanical attrition. The resultant enantiopure amino alcohol is converted to a 1,4-dideoxy-1,4-imino-D-ribitol building block that has been incorporated into a pharmacological chaperone for Gaucher disease. Residual lipase protein levels in the final API are controlled below 50 ng/g by ELISA testing, and the batch record includes a hold point after enzymatic reaction to validate that protease contamination from the enzyme preparation is below the detection limit using a fluorescent casein assay. If the starting amino alcohol contains residual Pd above 20 ppm from a prior step, the enzyme activity drops by 40% within the first 12 h, documented by a decreased initial rate (measured as µmol substrate converted per gram of biocatalyst per minute). Peptide nucleic acid oligomer functionalization through orthogonal protective group sculptureThe (3R,4R)-1-Boc-3-amino-4-hydroxypyrrolidine structure provides a conformationally restricted surrogate for the aminoethylglycine backbone of peptide nucleic acid (PNA) oligomers, where the endocyclic amine of the pyrrolidine ring—once the Boc is removed—serves as the attachment point for carboxymethyl nucleobase acetic acid monomers. In a published solid-phase synthesis protocol that uses fluorenylmethyloxycarbonyl (Fmoc) chemistry on a Rink amide resin (loading 0.38 mmol/g), the hydroxyl at C-4 is first converted to a levulinyl ester by treatment with levulinic acid (5.0 eq), N,N'-diisopropylcarbodiimide (5.0 eq), and 4-dimethylaminopyridine (0.10 eq) in DMF for 2 h at 25 °C. The levulinate ester is stable to the piperidine (20% v/v in DMF) used for Fmoc removal, yet is cleanly cleaved with hydrazine monohydrate (0.5 M in pyridine/acetic acid 3:2) at 20 °C for 10 min without affecting the Boc-carbamate. This orthogonality enables iterative elongation of the oligomer on the resin while the C-4 hydroxyl remains a latent functionality that can be liberated at the final step for postsynthetic conjugation to a fluorescent label or a cell-penetrating peptide. The coupling of thymine-1-acetic acid to the deprotected pyrrolidine nitrogen is performed using HBTU (4.0 eq) and NMM (8.0 eq) in NMP, and double couplings are required for residues beyond the eighth position; the average coupling efficiency as determined by Fmoc release is 98.7% per cycle.Residual solvents in the PNA oligomer after cleavage and precipitation are analyzed against ICH Q3C limits, and a typical batch shows acetonitrile at 350 ppm, N,N-dimethylformamide at 620 ppm, and dichloromethane below the limit of quantification (60 ppm). The PNA–drug conjugate targeting the bcl-2 mRNA splice junction is further purified by preparative reverse-phase HPLC on a C18 column (acetonitrile/0.1% TFA gradient) and lyophilized to yield a white powder with water content <8.0%. The key advantage conferred by the pyrrolidine scaffold is the Tm increase of +3.5 °C per modification when hybridized to complementary DNA, measured by UV melting curves at 260 nm in 10 mM phosphate-buffered saline, pH 7.4, containing 100 mM NaCl. This enhanced thermal stability reduces the overall required oligomer length, a factor that directly affects the cost of synthesis and the complexity of purification. A documented limitation is that the hydroxyl levulinate is susceptible to premature cleavage if the resin is stored for more than 48 h at 4 °C in an acidic environment (pH <5.0), resulting in a deletion sequence that co-elutes with the parent product and cannot be removed by standard ion-exchange chromatography. Comparative solvent compatibility during C-3 amine acylation of (3R,4R)-N-Boc-3-amino-4-hydroxypyrrolidine | Solvent System | Activator | Conversion (%) | O-Acylation Impurity (%) | Epimer at C-2 (%) | | THF/DMF (4:1) | HATU | 97.3 | 1.2 | <0.1 | | DCM/MeCN (1:1) | EDC·HCl + HOBt | 94.6 | 2.8 | 0.5 | | EtOAc | CDI | 88.9 | 0.7 | 0.2 | | 2-MeTHF | T3P (50% in EtOAc) | 91.2 | 1.9 | <0.1 | The data in the table were generated at 0.25 M substrate concentration with 1.00 eq of 4-pentynoic acid as a model substrate and 1.20 eq of activator, monitored by UPLC (Acquity BEH C18, 1.7 µm, 2.1 × 50 mm, 0.5 mL/min, 210 nm). The reaction temperature was maintained at 0 °C for the HATU and CDI systems, and at 22 °C for the remaining two. None of the conditions altered the Boc-carbamate integrity beyond 0.3% as measured by LC-MS. The O-acylation byproduct was identified as the 4-O-pentynoyl derivative by its characteristic doublet of doublets for H-4 in 1H NMR (δ 5.15 ppm, J = 4.8, 2.2 Hz). When the manufacturing process approaches kilogram scale for a partner contract development organization, the pyrophoric nature of borane reagents in the earlier reduction scheme mandates a dedicated hydrogenation suite with explosion-proof electrical classification. The pyrrolidine-derived ammonium salt is hygroscopic to a degree that pneumatic conveying in the final blending step requires dew-point monitoring of the conveying air at ≤–40 °C. A residual solvent panel is applied to each isolated intermediate per USP <467> procedure A, with acetonitrile, 1,4-dioxane, and DMF quantified by headspace GC-FID. Receiving-site quality agreements stipulate that any shipment with an enthalpy of fusion below 90 J/g by DSC (heating rate 10 K/min, nitrogen purge) is held for polymorph screening, as the appearance of a second crystal form has been traced to 0.3% isopropyl acetate carryover. That same form exhibits a solubility in water at 25 °C of 18 mg/mL versus 11 mg/mL for the desired morphology, a discrepancy that shifts the dissolution profile of the final dosage form during in vitro testing using USP apparatus II (paddle, 50 rpm, 37 °C, 900 mL of simulated intestinal fluid). These physical characterization gate checks are inserted into the manufacturing batch record immediately after drying, before the material enters the micronization step. Residual solvent compliance thresholds for intermediates derived from the pyrrolidine scaffold (ICH Q3C Option 1, Class 2 and 3 solvents) | Solvent | PDE (mg/day) | Concentration Limit (ppm) | Analytical Method | Typical Observed Level (ppm) | | Dichloromethane | 6.0 | 600 | Headspace GC-MS, 70 °C equilibration | 260 | | 1,4-Dioxane | 3.8 | 380 | Direct injection GC-FID, DB-624 column | <80 | | N,N-Dimethylformamide | 10.9 | 880 | HPLC-UV after derivatization | 210 | | Acetonitrile | 4.1 | 410 | Headspace GC-FID, 85 °C equilibration | 175 | | 2-Methyltetrahydrofuran | Not assigned (Class 3) | 5000 | Headspace GC-FID | 3200 | The limits in the table are applied at the point of release of the active pharmaceutical ingredient manufactured from the pyrrolidine intermediate. When a step employs 2-methyltetrahydrofuran as the extraction solvent, the drying cycle in the cone vacuum dryer is extended by 4 h at 55 °C jacket temperature until a sample withdrawn from the dryer shows a loss on drying below 0.5% w/w, ensuring that the residual level falls below 0.5% w/w and thus well within the ICH Class 3 default of 0.5% (5000 ppm). The drying vacuum setpoint is 20 mbar absolute. Any deviation from these parameters triggers a non-conformance investigation under the site’s Corrective and Preventive Action system, with a risk assessment matrix that evaluates the probability of solvent accumulation in the rotary lobe vacuum pump oil.
|
